EffPac Trial
Multicenter, randomized and controlled trial, Luminor vs POBA.
82.10% fTLR
at 5 years
Home
Applications
Endovascular
Peripheral
Luminor Paclitaxel eluting PTA balloon dilatation catheter
Peripheral
- GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface
- GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis
- GORE® VIATORR® TIPS Endoprosthesis
- Luminor Paclitaxel eluting PTA balloon dilatation catheter
- iVolution pro Self-expanding peripheral stent system
- Sergeant supporting catheter
- Oceanus PTA Peripheral Balloon
- CO2 Injector
Luminor Paclitaxel eluting PTA balloon dilatation catheter
- GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface
- GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis
- GORE® VIATORR® TIPS Endoprosthesis
- Luminor Paclitaxel eluting PTA balloon dilatation catheter
- iVolution pro Self-expanding peripheral stent system
- Sergeant supporting catheter
- Oceanus PTA Peripheral Balloon
- CO2 Injector
Luminor Paclitaxel eluting PTA balloon dilatation catheter
PRODUCT FEATURES
Easy navigation
Small profiles
Short deflation times and wide size range (0.014”, 0.018” and 0.035” guidewire compatibilities)
Coating technology matters
Not all DCBs are the same
TransferTech, the iVascular proprietary nanotechnology that:
Has an ultrathin coating thanks to the nanodrop technology used to coat the balloons.
Ensures a durable coating due to its multilayer technology, with minimum drug loss during navigation.
Ensures a uniform artery treatment.
CLINICAL SUPPORT
Luminor has demonstrated its safety and efficacy in long term follow-up and in different indications:
TINTIN Trial
Prospective, multicenter trial, with Luminor and iVolution combined therapy in TASC C&D lesions.
74.8% fTLR
at 4 years
MERLION Trial
Prospective, multicenter trial, with Luminor and Angiolite BTK as bailout stenting in BTK.
81.6% fTLR
at 1 year
Other trials: BIBLIOS, LUMBRA, LUMIFOLLOW, SOL JAPAN, LUMINOR registry.
CLINICAL PRESENTATIONS AT CONGRESSES
EffPac Trial
3.5 years outcomes presented at LINC 2021
TINTIN Trial
2-year outcomes presented at LINC 2021